Search Results

Genentech/Roche: winning streak continues for MabThera.

Subjects: RITUXIMAB; ANTINEOPLASTIC agents; CANCER chemotherapyGENENTECH Inc. GENENTECH Inc. GENENTECH Inc. DNA; F. Hoffmann-La Roche Ltd.

• Source: PharmaWatch: Cancer. June 2004, Vol. 3 Issue 6, p12-13. 2p.

Record details

Roche's MabThera exeeds expectations.

Subjects: RITUXIMAB; CLINICAL trials; DRUG developmentF. Hoffmann-La Roche Ltd.

• Source: PharmaWatch: Cancer. May 2004, Vol. 3 Issue 5, p12-13. 2p.

Record details

Genentech/Roche: winning streak continues for MabThera.

Subjects: *SALES; RITUXIMAB; ANTINEOPLASTIC agentsGENENTECH Inc. GENENTECH Inc. GENENTECH Inc. DNA; F. Hoffmann-La Roche Ltd.

• Source: PharmaWatch: Biotechnology. June 2004, Vol. 3 Issue 6, p4-5. 2p.

Record details

Biogen Idec/Genentech: promising phase II data for rituximab in MS.

Subjects: CLINICAL trials; RITUXIMAB; MULTIPLE sclerosis treatmentUNITED StatesBIOGEN Inc. (2003- ) BIOGEN Inc. (2003- ) BIOGEN Inc. (2003- ) BIIB; GENENTECH Inc. GENENTECH Inc. GENENTECH Inc. DNA

• Source: PharmaWatch: Biotechnology. Jun2007, Vol. 6 Issue 6, p4-4. 1p.

Record details

Dr. Reddy's proposed rituximab biosimilar application accepted for review by USFDA.

Subjects: RITUXIMABUNITED States. Food & Drug Administration

• Source: Ace Analyser: Company News; 7/13/2023, pN.PAG-N.PAG, 1p

Record details

Intas launches Rituximab biosimilar.

Subjects: RITUXIMAB; LYMPHOMA treatmentINTAS Pharmaceuticals Ltd.

• Source: BioSpectrum. Jun2013, Vol. 11 Issue 6, p85-85. 1/4p.

Record details

Genentech/Roche/Biogen Idec: Rituxan receives EU boost.

Subjects: CLINICAL trials; RITUXIMAB; MONOCLONAL antibodiesEUROPEAN Union

• Source: PharmaWatch: Biotechnology. Mar2009, Vol. 8 Issue 3, p9-9. 1p.

Record details

Roche: improved potential for MabThera.

Subjects: RITUXIMAB; CLINICAL trials; ANTINEOPLASTIC agentsF. Hoffmann-La Roche Ltd.

• Source: PharmaWatch: Cancer. January 2004, Vol. 3 Issue 1, p12-12. 1p.

Record details

Genentech/Roche/Biogen Idec: Rituxan receives EU boost.

Subjects: *SALES; *PHARMACEUTICAL industry; RITUXIMABEUROPE

• Source: PharmaWatch: Monthly Review. Mar2009, Vol. 8 Issue 3, p6-6. 1p.

Record details

Dr. Reddy's completes full set of clinical studies of rituximab biosimilar for filing in U.S., Europe.

Subjects: RITUXIMAB; EMERGING marketsINDIA

• Source: Ace Analyser: Company News; 1/20/2023, pN.PAG-N.PAG, 1p

Record details

Biogen Idec/Genentech: Promising phase II data for rituximab in MS.

Subjects: CLINICAL drug trials; MULTIPLE sclerosis treatment; RITUXIMABBIOGEN Inc. (2003- ); GENENTECH Inc.

• Source: PharmaWatch: CNS; Jun2007, Vol. 6 Issue 6, p4-4, 1p

Record details

IDEC-Genentech case study.

Subjects: BUSINESS partnerships; LYMPHOMAS; RITUXIMABGENENTECH Inc.; IDEC Pharmaceuticals Corp.

• Source: IDEC-Genentech Case Study: Successful Late Stage Licensing Strategies; Oct2005, p1-17, 17p

Record details

Drug pipeline suggests glimmer of hope for SLE sufferers.

Subjects: *PHARMACEUTICAL industry; SYSTEMIC lupus erythematosus treatment; DRUG developmentF. Hoffmann-La Roche Ltd.

• Source: PharmaWatch: Monthly Review. Nov2006, Vol. 5 Issue 11, p25-26. 2p.

Record details

Millennium initiates phase II clinical trial with Velcade and Rituximab.

Subjects: LYMPHOMA treatment; RETICULOENDOTHELIAL granulomas; PHARMACEUTICAL industryMILLENNIUM Pharmaceuticals Inc.

• Source: PharmaWatch: Cancer; June 2004, Vol. 3 Issue 6, p17-17, 1p

Record details

Monoclonal antibody market growth set to outstrip small molecules.

Subjects: MONOCLONAL antibodies; IMMUNOGLOBULINS; PHARMACEUTICAL industryUNITED States

• Source: PharmaWatch: Biotechnology; Nov2007, Vol. 6 Issue 11, p22-24, 3p

Record details

Biogen Idec/Genentech: Promising phase II data for rituximab in MS.

Subjects: CLINICAL drug trials; DRUG development; BRAIN tumor treatmentBIOGEN Inc. (2003- )

• Source: PharmaWatch: Monthly Review; Jun2007, Vol. 6 Issue 6, p39-39, 2/3p

Record details

LATEST RESEARCH: Rituximab for RA: Persistence Pays Off.

• Source: Arthritis; Jan2011, p55-55, 1/3p

Record details

Genmab initiates Phase III lymphoma trial.

Subjects: CLINICAL trials; DRUG therapy; B cell lymphomaGENMAB A/S

• Source: PharmaWatch: Cancer; Dec2009, Vol. 8 Issue 12, p6-7, 2p

Record details

Cephalon submits NDA for lymphoma drug.

Subjects: DRUG development; LYMPHOMAS; RITUXIMABCEPHALON Inc.

• Source: PharmaWatch: Cancer; Feb2008, Vol. 7 Issue 2, p4-4, 1/2p

Record details

Cephalon wins FDA approval for lymphoma drug.

Subjects: DRUG approval; HODGKIN'S disease treatment; RITUXIMABUNITED StatesUNITED States. Food & Drug Administration; CEPHALON Inc.

• Source: PharmaWatch: Biotechnology; Dec2008, Vol. 7 Issue 12, p12-12, 1/2p

Record details

Genta initiates trial of Genasense in chronic lymphocytic leukemia.

Subjects: CLINICAL trials; CHRONIC lymphocytic leukemia; ANTINEOPLASTIC agents

• Source: PharmaWatch: Cancer; September 2003, Vol. 2 Issue 9, p14-15, 2p

Record details

Millennium initiates Phase II lymphoma trial.

Subjects: LYMPHOMAS; CLINICAL trials; RITUXIMABTAKEDA Oncology Co.SIMONIAN, Nancy

• Source: PharmaWatch: Cancer; Dec2009, Vol. 8 Issue 12, p5-5, 2/3p

Record details

Genentech/Biogen Idec: Rituxan fails Phase II/III SLE trial.

Subjects: *PHARMACEUTICAL industry; CLINICAL trials; DRUG efficacyGENENTECH Inc. GENENTECH Inc. GENENTECH Inc. DNA; BIOGEN Inc. (2003- ) BIOGEN Inc. (2003- ) BIOGEN Inc. (2003- ) BIIB

• Source: PharmaWatch: Monthly Review. Jun2008, Vol. 7 Issue 6, p22-22. 1p.

Record details

Clinical data describes activity of Nipent in non-Hodgkin's lymphoma.

Subjects: ANTINEOPLASTIC agents; LYMPHOMAS; CLINICAL trialsASTEX Pharmaceuticals Inc.

• Source: PharmaWatch: Biotechnology; January 2004, Vol. 3 Issue 1, p8-8, 1p

Record details

Corixa/GSK: Bexxar on the market.

Subjects: CANCER treatment; RITUXIMAB; DRUG therapyCORIXA Corp.; GLAXOSMITHKLINE

• Source: PharmaWatch: Cancer; September 2003, Vol. 2 Issue 9, p13-13, 1p

Record details

Lymphoma Update.

Subjects: LYMPHOMA treatment; DRUGS; RETICULOENDOTHELIAL granulomasGLAXOSMITHKLINE; MILLENIUM Pharmaceuticals Inc.

• Source: PharmaWatch: Cancer; July 2005, Vol. 4 Issue 7, p13-15, 3p

Record details

Dr. Reddy's Laboratories informs about press release.

Subjects: PRESS releases; BUSINESS enterprisesDR. Reddy's Laboratories Ltd.

• Source: Ace Analyser: Company News; 1/20/2023, pN.PAG-N.PAG, 1p

Record details

Results Update.

Subjects: CLINICAL medicine research; CANCER in women; HODGKIN'S disease treatmentGLAXOSMITHKLINE; GENMAB A/S; GENENTECH Inc.

• Source: PharmaWatch: Cancer; Oct2009, Vol. 8 Issue 10, p6-7, 2p

Record details

Hutchmed China Ltd SWOT Analysis.

• Source: Hutchmed China Ltd. SWOT Analysis; 2/1/2024, p1-7, 7p

Record details

Hutchmed China Ltd SWOT Analysis.

• Source: Hutchmed China Ltd. SWOT Analysis; 12/28/2023, p1-7, 7p

Record details

ImmunoGen, Inc. SWOT Analysis.

• Source: ImmunoGen, Inc. SWOT Analysis; 9/19/2023, p1-7, 7p

Record details

Drug Repositioning case study.

Subjects: MARKET positioning; DRUG laws; PHARMACY

• Source: Drug Repositioning Case Study: Repositioning Drugs Either Serendipitously Or By Informed Insight; May2008, p1-15, 15p, 9 Diagrams

Record details

Research Update.

Subjects: CLINICAL medicine research; HODGKIN'S disease; SMALL cell lung cancerSEATTLE Genetics Inc.; ANTISOMA PLC

• Source: PharmaWatch: Cancer; Oct2009, Vol. 8 Issue 10, p5-6, 2p

Record details

FDA accepts Cephalon's NDA for lymphoma drug.

Subjects: DRUG approval; LYMPHOMA treatment; HODGKIN'S disease treatmentUNITED StatesCEPHALON Inc.; UNITED States. Food & Drug Administration

• Source: PharmaWatch: Biotechnology; Apr2008, Vol. 7 Issue 4, p10-11, 2p

Record details

COMPANY SPOTLIGHT - Genentech, Inc.

Subjects: DRUGS; IMMUNOLOGY; CANCER treatmentGENENTECH Inc.; IDEC Pharmaceuticals Corp.

• Source: PharmaWatch: Monthly Review; August 2005, Vol. 4 Issue 8, p56-59, 4p

Record details

COMPANY SPOTLIGHT - Genentech.

Subjects: BUSINESS enterprises; BIOTECHNOLOGY industries; PHARMACEUTICAL industryUNITED StatesGENENTECH Inc.

• Source: PharmaWatch: Cancer; Apr2005, Vol. 4 Issue 4, p21-26, 6p

Record details

Lymphoma Update.

Subjects: PHARMACEUTICAL industry; LYMPHOMASUNITED StatesCLINICAL Data Inc.; BERLEX Oncology (Company); FAVRILLE Inc.

• Source: PharmaWatch: Cancer; Dec2006, Vol. 5 Issue 12, p4-5, 2p

Record details

LATEST COMPANY NEWS.

• Source: Germany Pharmaceutical. 2023.

Record details

Indonesia - Pharmaceuticals.

• Source: Pharmaceuticals in Indonesia. 2023.

Record details

ImmunoGen, Inc. SWOT Analysis.

Subjects: PHARMACEUTICAL industry; SWOT analysisWALTHAM (Mass.)IMMUNOGEN Inc.

• Source: ImmunoGen, Inc. SWOT Analysis; 12/13/2022, p1-7, 7p

Record details

Rheumatoid arthritis: NICE recommendation to boost UK market.

Subjects: RHEUMATOID arthritis treatment; TUMOR necrosis factors; GUIDELINESUNITED KingdomNATIONAL Institute for Health & Care Excellence (Great Britain)

• Source: PharmaWatch: Monthly Review; Aug2010, Vol. 9 Issue 8, p17-17, 1p

Record details

FDA accepts Cephalon's NDA for lymphoma drug.

Subjects: DRUG approval; ANTINEOPLASTIC agents; B cellsCEPHALON Inc.; UNITED States. Food & Drug Administration

• Source: PharmaWatch: Cancer; Apr2008, Vol. 7 Issue 4, p5-5, 1/4p

Record details

Lymphoma Update.

Subjects: LYMPHOMAS; CANCER treatment; PHARMACEUTICAL industryPHARMION Corp.; DR. Reddy's Laboratories Ltd.; CYDEX Pharmaceuticals Inc.

• Source: PharmaWatch: Cancer; Jun2007, Vol. 6 Issue 6, p4-5, 2p

Record details

Clinical Trials Update.

Subjects: MEDICAL research; DRUG development; CANCER patientsGENMAB A/S

• Source: PharmaWatch: Biotechnology; July 2005, Vol. 4 Issue 7, p6-7, 2p

Record details

LATEST COMPANY NEWS.

• Source: Japan Food Processing. 2023.

Record details

ImmunoGen, Inc. SWOT Analysis.

Subjects: PHARMACEUTICAL industry; SWOT analysisWALTHAM (Mass.)IMMUNOGEN Inc.

• Source: ImmunoGen, Inc. SWOT Analysis; 11/29/2021, p1-7, 7p

Record details

STADA Arzneimittel AG SWOT Analysis.

Subjects: PHARMACEUTICAL industry; SWOT analysis; BUSINESS financeSTADA Arzneimittel AG

• Source: STADA Arzneimittel AG SWOT Analysis; Jan2013, p1-7, 7p

Record details

Roche Holding Ltd.

Subjects: BUSINESS finance; BUSINESS cycles; INDUSTRIAL locationF. Hoffmann-La Roche Ltd.

• Source: Roche Group SWOT Analysis; Sep2008, p1-11, 11p, 2 Charts

Record details

COMPANY SPOTLIGHT - Roche.

Subjects: PHARMACEUTICAL industry; DRUGS; THERAPEUTICSSWITZERLANDF. Hoffmann-La Roche Ltd.

• Source: PharmaWatch: Cancer; Sep2008, Vol. 7 Issue 9, p18-26, 9p

Record details

COMPANY SPOTLIGHT - Roche.

Subjects: HOLDING companies; PHARMACEUTICAL industry; SUPPLIERSSWITZERLANDF. Hoffmann-La Roche Ltd.

• Source: PharmaWatch: Monthly Review; Sep2008, Vol. 7 Issue 9, p38-46, 9p

Record details